Avita Medical Inc

Financials

Flujo de caja de las actividades operativas -25.9 M-19.09 M-38.01 M-48.94 M-31.2 M -31.2 M Flujo de caja de las actividades de inversión -1.17 M-19.33 M1.61 M37.36 M12.45 M 12.45 M Flujo de caja de las actividades financieras 64.05 M900 K40.37 M3.51 M14.94 M 14.94 M Flujo de caja libre -27.07 M-19.61 M-39.46 M-58.27 M-32.93 M -32.3 M

Avita Medical is a clinical and commercial company developing and marketing a range regenerative medicine products. The first regenerative medicine product brought to the market by Avita Medical was ReCell spray-on skin for the treatment of burns. The two latest products are ReNovaCell, for Aesthetics and Plastic applications including skin trauma, and ReGenerCell for the treatment of chronic wounds. The Avita Medical regenerative product range is currently marketed in Europe, the Middle East, Africa and Australia.

RCEL

Financials

Avita Medical Inc

Noticias

AVITA Medical: Why The BARDA Rally Changes Nothing (NASDAQ:RCEL)

AVITA Medical obtiene contrato de 25,5 millones de dólares con BARDA

Avita Medical en la Conferencia de TD Cowen: Crecimiento y enfoque estratégico

Avita Medical en Conferencia TD Cowen: Crecimiento y Enfoque Estratégico

Avita Medical at TD Cowen Conference: Growth and Strategic Focus

Wall Street Analysts Believe Avita Medical (RCEL) Could Rally 29.87%: Here's is How to Trade

Avita Medical (RCEL) Upgraded to Buy: Here's What You Should Know

AVITA Medical, Inc. (RCEL) Discusses Financial Performance, Sales Strategy, and Reimbursement Progress Transcript

AVITA Medical, Inc. (RCEL) Q4 2025 Earnings Call Transcript

Avita Medical: Crecimiento anual del 11% en 4T 2025 con expansión del 12-19% para 2026

Avita Medical T4 2025: crecimiento anual del 11% con expansión del 12-19% prevista para 2026

Avita Medical Q4 2025 slides: 11% annual growth with 12-19% expansion targeted for 2026